Roswell Park Cancer Institute (RPCI) has enhanced Institute science and education activities over the current period of NCI funding. Critical to this progress has been the availability of the CCSG Developmental Funds which serve to nucleate investment of philanthropic and Institute resources for expansion of science and education. The success of these investments is greatly enhanced by effective RPCI Planning and Evaluation processes that identify and evaluate areas of strategic opportunity and need. These processes engage advisory committees (e.g. CCSG External Advisory Board, program-specific External Advisory Boards, Executive Council, CCSG Steering Committee, Shared Resource Directors Committee, Shared Resource Advisory Committees and Institute Strategic Leadership Retreats). High priority needs are identified, and met through the use of Institute funds and philanthropic resources, with a small but very important component (3%) constituted by CCSG Developmental Funds. Developmental Funds are used to recruit outstanding basic, clinical and population scientists, to enhance shared resource infrastructure and to promote programmatic research in strategic high priority areas. During the award period, these funds were used to recruit 17 new CCSG members, 13 of whom have obtained extramural peer-reviewed project or career-development funding with a return on investment (grant funding) of 24:1. Nine (9) shared resources received developmental funding, and this resulted in more use by investigators, enhanced recruitment efforts and additional peer-reviewed funding opportunities. Sixteen (16) research projects were awarded that to date have generated 6 grants or funded supplements (with a well-scored P50 awaiting funding), 8 publications, 9 abstracts, and 5 clinical trials with a return on investment (grant funding) of 11:1. Institute and CCSG Developmental Funds are complemented by philanthropic funding through the Roswell Park Alliance Foundation (RPAF) to reach key Institute strategic goals. In the next award period, RPCI proposes to utilize CCSG Developmental Funds for continued support of faculty recruitment, shared resources and developmental research. These will be strategically selected in accordance with the RPCI strategic plan and ongoing review by evaluation processes. Dr. Donald Trump, Institute Director, has responsibility for final assignment of CCSG and Institute funds.

Public Health Relevance

To drive growth and innovation, Roswell Park Cancer Institute strategically uses developmental funding to support strategic faculty recruitment, novel pilot projects, and shared resource development. These areas are closely tied to going strategic planning and evaluation efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-37
Application #
8738380
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-06-16
Project End
2019-04-30
Budget Start
2014-06-26
Budget End
2015-04-30
Support Year
37
Fiscal Year
2014
Total Cost
$858,627
Indirect Cost
$339,621
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
McManus, Hallie; Moysich, Kirsten B; Tang, Li et al. (2018) Usual Cruciferous Vegetable Consumption and Ovarian Cancer: A Case-Control Study. Nutr Cancer 70:678-683
Welliver, R Ross; Polanco, Jessie J; Seidman, Richard A et al. (2018) Muscarinic receptor M3R signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells. J Neurosci :
Widman, Christy A; Rodriguez, Elisa M; Saad-Harfouche, Frances et al. (2018) Clinician and Parent Perspectives on Educational Needs for Increasing Adolescent HPV Vaccination. J Cancer Educ 33:332-339
Wang, Yuliang; Eng, Diana G; Pippin, Jeffrey W et al. (2018) Sex differences in transcriptomic profiles in aged kidney cells of renin lineage. Aging (Albany NY) 10:606-621
Zakharia, Yousef; Bhattacharya, Arup; Rustum, Youcef M (2018) Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development. Oncotarget 9:10765-10783
Sharma, Umesh C; Sonkawade, Swati D; Spernyak, Joseph A et al. (2018) A Small Peptide Ac-SDKP Inhibits Radiation-Induced Cardiomyopathy. Circ Heart Fail 11:e004867
Wang, Xue; Niu, Jin; Li, Jun et al. (2018) Temporal Effects of Combined Birinapant and Paclitaxel on Pancreatic Cancer Cells Investigated via Large-Scale, Ion-Current-Based Quantitative Proteomics (IonStar). Mol Cell Proteomics 17:655-671
Burkard-Mandel, Lauren; O'Neill, Rachel; Colligan, Sean et al. (2018) Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism. Oncoimmunology 7:e1419115
Rosario, S R; Long, M D; Affronti, H C et al. (2018) Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. Nat Commun 9:5330
Tsuji, Takemasa; Yoneda, Akira; Matsuzaki, Junko et al. (2018) Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy. Cancer Immunol Res 6:594-604

Showing the most recent 10 out of 1555 publications